Monitoring Desk
BEIJING: National Medical Products Administration said Sunday that China has conducted emergency reviews and given conditional approval for 2 homegrown drugs for Covid-19 treatment.
The applications for the innovative drugs VV116 and XIANNUOXIN were submitted by a subsidiary of Shanghai Junshi Biosciences and Simcere, respectively.
Both are oral small-molecule medicines intended to be used for the treatment of adults suffering from mild to moderate COVID-19.
Drugs to be used with doctors’ guidance
The administration cautioned that the patients should strictly follow the doctors’ guidance while taking the drugs.
